Skip to main content
. 2021 Apr 19;320(6):F1133–F1151. doi: 10.1152/ajprenal.00614.2020

Figure 1.

Figure 1.

Sacubitril/valsartan (Sac/Val) treatment improved urine parameters and podocyte density in db/db mice. A: urinary albumin, kidney injury molecule-1 (KIM-1), and neutrophil gelatinase-associated lipocalin (NGAL) were measured in 24-h urine. Urinary albumin, KIM-1, and NGAL excretion were markedly increased in db/db mice compared with nondiabetic db/m controls. Administration with Sac/Val and Val significantly decreased urinary albumin, KIM-1, and NGAL levels; n = 10 or 11 per group. B: immunofluorescence staining of kidney sections for the podocyte marker synaptopodin showed decreased podocyte density represented by the ratio of the synaptopodin-positive area vs. glomerular tuft area in db/db kidneys, which was prevented by Sac/Val or Val treatment; n = 6 per group. Data are presented as means ± SE. uACR, urine albumin-to-creatinine (Cr) ratio; Veh, vehicle.